Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial.
Eugenio Paci,Donella Puliti,Andrea Lopes Pegna,Laura Carrozzi,Giulia Picozzi,Fabio Falaschi,Francesco Pistelli,Ferruccio Aquilini,Cristina Ocello,Marco Zappa,Francesca Carozzi,Mario Mascalchi +11 more
Reads0
Chats0
TLDR
The ITALUNG trial outcomes suggest that LDCT screening could reduce LC and overall mortality and the comparison of the number of LC cases diagnosed in the two groups does not show overdiagnosis after an adequate follow-up period.Abstract:
Background ITALUNG is contributing to the European evaluation of low-dose CT (LDCT) screening for lung cancer (LC). Methods Eligible subjects aged 55–69 years, smokers or ex-smokers (at least 20 pack-years in the last 10 years), were randomised to receive an annual invitation for LDCT screening for 4 years (active group) or to usual care (control group). All participants were followed up for vital status and cause of death (at the end of 2014) and LC incidence (at the end of 2013). Pathological and clinical information was collected from the Tuscan Cancer Registry data. Results 1613 subjects were randomly assigned to the active group and 1593 to the control group. At the end of the follow-up period 67 LC cases were diagnosed in the active group and 71 in the control group (rate ratio (RR)=0.93; 95% CI 0.67 to 1.30). A greater proportion of stage I LC was observed in the active group (36% vs 11%, p Conclusions Despite the lack of statistical significance, the ITALUNG trial outcomes suggest that LDCT screening could reduce LC and overall mortality. Moreover, the comparison of the number of LC cases diagnosed in the two groups does not show overdiagnosis after an adequate follow-up period. A pooled analysis of all European screening trials is advocated to assess the benefit-to-harm ratio of LDCT screening and its implementation in public health settings. Trial registration number Results, NCT02777996.read more
Citations
More filters
Journal ArticleDOI
Progress and prospects of early detection in lung cancer
Sean Knight,Phil A. Crosbie,Haval Balata,Jakub Chudziak,Tracy Hussell,Caroline Dive,Caroline Dive +6 more
TL;DR: Despite significant developments in the oncological management of late stage lung cancer over recent years, survival remains poor and the UK Office for National Statistics reported that patients diagnosed with distant metastatic disease had a 1-year survival rate of just 15–19% compared with 81–85% for stage I.
Journal ArticleDOI
European position statement on lung cancer screening
Matthijs Oudkerk,Anand Devaraj,Rozemarijn Vliegenthart,Thomas Henzler,Helmut Prosch,Claus P. Heussel,Claus P. Heussel,Gorka Bastarrika,Nicola Sverzellati,Mario Mascalchi,Stefan Delorme,David R Baldwin,Matthew E.J. Callister,Nikolaus Becker,Marjolein A Heuvelmans,Witold Rzyman,Maurizio Infante,Ugo Pastorino,Jesper Holst Pedersen,Eugenio Paci,Stephen W. Duffy,Harry J. de Koning,John K. Field +22 more
TL;DR: A risk stratification approach should be used for future lung cancer low-dose CT programmes and patients should be provided with information on the benefits and harms of screening to ensure that patients receive the most appropriate treatment.
Journal ArticleDOI
Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy
Ugo Pastorino,Mario Silva,Stefano Sestini,Federica Sabia,Mattia Boeri,Anna Cantarutti,Nicola Sverzellati,Gabriella Sozzi,Giovanni Corrao,Alfonso Marchianò +9 more
TL;DR: The MILD trial provides additional evidence that prolonged screening beyond 5 years can enhance the benefit of early detection and achieve a greater overall and LC mortality reduction compared with NLST trial.
Journal ArticleDOI
Screening for Lung Cancer: CHEST Guideline and Expert Panel Report
Peter J. Mazzone,Gerard A. Silvestri,Sheena Patel,Jeffrey P. Kanne,Linda S. Kinsinger,Renda Soylemez Wiener,Guy W. Soo Hoo,Frank C. Detterbeck +7 more
TL;DR: The updated evidence base is used to provide recommendations where the evidence allows, and statements based on experience and expert consensus where it does not, and to optimize the approach to low‐dose CT screening.
Journal ArticleDOI
Lung cancer mortality reduction by LDCT screening-Results from the randomized German LUSI trial.
Nikolaus Becker,Erna Motsch,Anke Trotter,Claus P. Heussel,Hendrik Dienemann,Philipp A. Schnabel,Hans-Ulrich Kauczor,Sandra González Maldonado,Anthony B. Miller,Rudolf Kaaks,Stefan Delorme +10 more
TL;DR: Findings from LUSI are in line with those from other trials, including NLST, that suggest a stronger reduction of lung cancer mortality after LDCT screening among women as compared to men, and heterogeneity could be the result of different relative counts of lung tumor subtypes occurring in men and women.
References
More filters
Journal ArticleDOI
Reduced lung-cancer mortality with low-dose computed tomographic screening.
Denise R. Aberle,Amanda M. Adams,Christine D. Berg,William C. Black,Jonathan D. Clapp,Richard M. Fagerstrom,Ilana F. Gareen,Constantine Gatsonis,Pamela M. Marcus,JoRean D. Sicks +9 more
TL;DR: Screening with the use of low-dose CT reduces mortality from lung cancer, as compared with the radiography group, and the rate of death from any cause was reduced.
Book
International Classification of Diseases for Oncology
TL;DR: This list of diseases for oncology includes cancers of the central nervous system, as well as other types of diseases such as lymphoma, leukaemia, and so on.
Journal ArticleDOI
International Classification of Diseases for Oncology
TL;DR: Use ofImmunofluorescence in the Diagnosis of Virus Infections using audio-tape slide programme and slides and cassette by P. S. Gardner.
Journal ArticleDOI
Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement
TL;DR: Although lung cancer screening is not an alternative to smoking cessation, the USPSTF found adequate evidence that annual screening for lung cancer with LDCT in a defined population of high-risk persons can prevent a substantial number of lung cancerrelated deaths.
Related Papers (5)
Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography
Maurizio Infante,Silvio Cavuto,Fabio Romano Lutman,Eliseo Passera,Maurizio Chiarenza,G Chiesa,Giorgio Brambilla,Enzo Angeli,Giuseppe Aranzulla,Arturo Chiti,Marta Scorsetti,Pierina Navarria,Raffaele Cavina,Michele Ciccarelli,Massimo Roncalli,Anna Destro,Edoardo Bottoni,Emanuele Voulaz,Valentina Errico,Giorgio Maria Ferraroli,Giovanna Finocchiaro,Luca Toschi,Armando Santoro,Marco Alloisio +23 more
Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial
Harry J. de Koning,Carlijn M. van der Aalst,Pim A. de Jong,Ernst Th. Scholten,Kristiaan Nackaerts,Marjolein A Heuvelmans,Jan-Willem J. Lammers,Carla Weenink,Uraujh Yousaf-Khan,Nanda Horeweg,Susan van 't Westeinde,Mathias Prokop,Willem P.Th.M. Mali,Firdaus A. A. Mohamed Hoesein,Peter M. A. van Ooijen,Joachim G.J.V. Aerts,Michael A. den Bakker,Erik Thunnissen,Johny Verschakelen,Rozemarijn Vliegenthart,Joan Walter,Kevin ten Haaf,Harry J.M. Groen,Matthijs Oudkerk +23 more